A clinical trial found that a new technology called "bionic pancreas" may control blood sugar levels in patients with diabetes patients with diabetes better than standard insulin treatment.
This number introduced the oral insulin (
1
—
"artificial pancreas" system
Traditionally, patients with type 1 diabetes need to measure their blood sugar levels multiple times a day and then inject appropriate amounts of insulin.
Currently, some wearable devices make the above treatment easier, such as , a hybrid closed-loop system composed of a continuous blood sugar monitor and an insulin pump, . The continuous blood sugar monitor tracks blood sugar levels through a subcutaneous sensor, and then automatically adjusts the dose of insulin delivered by the insulin pump through certain algorithms.
These mixed closed-loop systems are sometimes called " artificial pancreas " system. The brands on the market include MiniMed, Control-IQ, etc. Although these devices are rapidly updated, they still require continuous efforts to invest. For example, in order to get the correct insulin dose before meals, users must calculate the number of carbohydrate grams in the food they will eat and adjust the insulin dose.
2
—
bionic pancreas
Compared with these "artificial pancreas" systems, bionic pancreas ruled out the above mathematical problems. Bionic pancreas also integrates insulin pumps and blood sugar monitors (Dexcom G6 Continuous Blood Glucose Monitor), but does not need to calculate the carbohydrate content. Accordingly, the user only needs to enter whether he is eating, Chinese or dinner, and whether he is eating as usual. The bionic pancreas will automatically determine the insulin dose given by .
All blood sugar correction delivery is completely automated and the user cannot modify the dose. When data from continuous blood glucose monitoring is not available, the bionic pancreas will automatically give 75% basal insulin.
This bionic pancreatic device is called iLet, which manages insulin and glucagon . iLet is currently under review by the US FDA. If approved by the latter, the iLet system will become the most automated type 1 diabetes management system in . The iLet system can track the blood sugar level of patients and automatically inject the minimum dose of insulin when needed.
3
—
comparison of bionic pancreas and artificial pancreatic systems
in this article Engl J In the Med clinical trial, diabetic patients aged 6-79 were randomly assigned to the bionic pancreas group or standard treatment control group (using a mixed closed-loop system, a conventional insulin pump or injection).
study found that at 13 weeks of use, the average level of 1 glycated hemoglobin decreased by 8% in patients with bionic pancreas . , but the glycated hemoglobin level in the standard treatment control group did not decrease.
And, compared with the standard treatment control group, used bionic pancreas for 2 and a half hours more than the daily blood sugar level.
4
—
Advantages of bionic pancreas
Compared with the mixed closed-loop system on the market, bionic pancreas is equivalent to providing an insulin delivery device that operates "fool" style.
The advantage of bionic pancreas is that does not require special calculations or complex settings for , and only needs to enter the weight at the initial stage. Bionic pancreas automatically determines and delivers the required insulin dose based on the weight, and there is no running-in period.
. Currently, the commercially-used automated or semi-automated hybrid closed-loop system requires calculation and input of carbohydrates to insulin ratio, total daily dose of insulin, and other parameters, and has a warm-up period.
In adults and children with type 1 diabetes, the mean blood sugar levels in patients with bionic pancreas for three months of use of bionic pancreas significantly, the control effect is better than the current hybrid closed-loop system, and there is no potentially dangerous hypoglycemia level.
Nevertheless, the long-term risks of using bionic pancreas need attention. The incidence of severe hypoglycemia in patients with bionic pancreas is 17.7% annually, higher than that of other insulin treatment options, although the statistical differences are not significant.
Reference Welcome to forward to family and friends in need.
Diabetes Technol Ther. 2022 Oct
N Engl J Med. 2022 Sep
Front Endocrinol. 2022 Jun
